Literature DB >> 29147803

Secondary resistance to tolvaptan in two patients with SIAD due to small cell lung cancer.

A Garrahy1, A M Hannon2, H M Zia-Ul-Hussnain2, D J Williams3, C J Thompson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29147803     DOI： 10.1007/s00228-017-2363-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  3 in total

1.  Oral tolvaptan is safe and effective in chronic hyponatremia.

Authors:  Tomas Berl; Friederike Quittnat-Pelletier; Joseph G Verbalis; Robert W Schrier; Daniel G Bichet; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 10.121

2.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Authors:  Robert W Schrier; Peter Gross; Mihai Gheorghiade; Tomas Berl; Joseph G Verbalis; Frank S Czerwiec; Cesare Orlandi
Journal:  N Engl J Med       Date:  2006-11-14       Impact factor: 91.245

3.  Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety.

Authors:  Abdulla K Salahudeen; Najeeba Ali; Marina George; Amit Lahoti; Shana Palla
Journal:  Cancer       Date:  2013-11-05       Impact factor: 6.860
  3 in total
  1 in total

Review 1.  The management of acute and chronic hyponatraemia.

Authors:  Sarah Jean Lawless; Chris Thompson; Aoife Garrahy
Journal:  Ther Adv Endocrinol Metab       Date:  2022-05-14       Impact factor: 4.435
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.